Constipation Treatment

A Global Strategic Business Report

MCP16287


EXECUTIVE INSIGHTS
DOMAIN EXPERTS
PLAYERS
PARTICIPANTS
  • NOV 2024
  • EDITION 9
  • TABLES 123
  • REGIONS 26
  • SEGMENTS 8
  • PAGES 194
  • US$ 5450
  • MCP16287
  • JOIN OUR PANEL

EXECUTIVE ENGAGEMENTS BY TIER

  • CXO

  • VICE PRESIDENT

  • DIRECTOR

  • MANAGER

  • MARKETING

REQUEST FULL-STACK INDEX

Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM
  

HIGHLIGHTS & REPORT INDEX

Global Constipation Treatment Market to Reach US$27.5 Billion by 2030

The global market for Constipation Treatment estimated at US$18.4 Billion in the year 2023, is expected to reach US$27.5 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030. Laxatives, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$12.3 Billion by the end of the analysis period. Growth in the Chloride Channel Activators segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.9 Billion While China is Forecast to Grow at 8.9% CAGR

The Constipation Treatment market in the U.S. is estimated at US$4.9 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.4 Billion by the year 2030 trailing a CAGR of 8.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Constipation Treatment Market – Key Trends & Drivers Summarized

Why Is There Increasing Demand for Constipation Treatment Solutions?
The growing prevalence of gastrointestinal disorders, particularly constipation, is driving demand for treatment solutions globally. Factors such as aging populations, sedentary lifestyles, poor dietary habits, and increasing levels of stress contribute to rising incidences of constipation, especially in developed regions. Moreover, constipation is a common side effect of medications used to treat chronic conditions like pain, hypertension, and diabetes. This has led to an increasing need for effective over-the-counter (OTC) laxatives, prescription medications, and natural remedies to alleviate symptoms and improve patients` quality of life.

How Are Technological and Pharmaceutical Innovations Impacting Constipation Treatment?
Pharmaceutical companies are continuously innovating to develop more effective and patient-friendly treatment options for constipation. Recent advancements include the development of novel laxatives with fewer side effects, such as osmotic laxatives, as well as medications like prokinetics that stimulate intestinal motility. Additionally, the rise of probiotics and fiber supplements as natural alternatives for managing constipation is gaining popularity, particularly among health-conscious consumers. Innovations in drug delivery mechanisms, such as extended-release formulations, are also helping to enhance treatment efficacy and patient compliance.

Which Demographic Segments Are Leading the Demand for Constipation Treatment?
The elderly population is a significant driver of demand for constipation treatments, as aging often leads to slower digestive function and increased reliance on medications that may cause constipation. Additionally, patients with chronic illnesses, such as irritable bowel syndrome (IBS), are frequent consumers of constipation treatment products. The increasing awareness of gastrointestinal health among younger populations is also fueling demand for OTC laxatives, natural remedies, and dietary supplements. Healthcare professionals are increasingly recommending preventive measures, including lifestyle modifications, to address chronic constipation, further driving the use of treatment solutions.

What Are the Key Growth Drivers of the Constipation Treatment Market?
The growth in the constipation treatment market is driven by several factors, including the increasing prevalence of gastrointestinal disorders, the growing aging population, and the rise in demand for OTC medications. The expanding awareness of digestive health and the rising trend toward self-medication are also boosting the demand for natural and OTC treatment options. Pharmaceutical advancements, such as the development of novel drugs with fewer side effects and more targeted action, are further contributing to market growth. Additionally, the increasing focus on preventive healthcare and lifestyle management is driving the adoption of dietary supplements and probiotics.

SCOPE OF STUDY

The report analyzes the Constipation Treatment market by the following Segments, and Geographic Regions/Countries:

Segments:
Disease Type (Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C), Opioid-Induced Constipation (OIC)); Therapeutic Option (Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists, 5-HT4 Receptor Agonists).

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa..

SELECT PLAYERS

Abbott; AbbVie`s Inc.; Albireo Pharma, Inc.; AstraZeneca; Bausch Health Companies Inc.; Bayer AG; Cosmo Pharma; Daewoong; Ironwood Pharmaceuticals; Janssen Pharmaceutical; Mallinckrodt Plc; Prestige Brands; Renexxion; Sanofi; Shionogi; Takeda Pharmaceutical Company Limited

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Constipation Treatment – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for 41 Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Growing Prevalence of Gastrointestinal Disorders
Increasing Demand for Over-the-counter Laxatives and Natural Remedies
Technological Advancements in Prescription Medications
Rising Use of Probiotics and Fiber Supplements in Constipation Management
Expanding Geriatric Population Driving Demand for Treatment Solutions
Growing Awareness of Digestive Health and Preventive Care
Increased Adoption of Combination Therapies for Chronic Conditions
Rise in Demand for Home-based Constipation Treatment Products
Rising Focus on Gut Health and Holistic Treatment Approaches
Growing Popularity of Personalized Medicine in Constipation Treatment
4. GLOBAL MARKET PERSPECTIVE
World Constipation Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
World Recent Past, Current & Future Analysis for Constipation Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
World Historic Review for Constipation Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
World 16-Year Perspective for Constipation Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
World Recent Past, Current & Future Analysis for Laxatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
World Historic Review for Laxatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
World 16-Year Perspective for Laxatives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
World Recent Past, Current & Future Analysis for Chloride Channel Activators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
World Historic Review for Chloride Channel Activators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
World 16-Year Perspective for Chloride Channel Activators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
World Recent Past, Current & Future Analysis for Peripherally Acting Mu-Opioid Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
World Historic Review for Peripherally Acting Mu-Opioid Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
World 16-Year Perspective for Peripherally Acting Mu-Opioid Receptor Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
World Recent Past, Current & Future Analysis for GC-C Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
World Historic Review for GC-C Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
World 16-Year Perspective for GC-C Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
World Recent Past, Current & Future Analysis for 5-HT4 Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
World Historic Review for 5-HT4 Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
World 16-Year Perspective for 5-HT4 Receptor Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
World Recent Past, Current & Future Analysis for Chronic Idiopathic Constipation (CIC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
World Historic Review for Chronic Idiopathic Constipation (CIC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
World 16-Year Perspective for Chronic Idiopathic Constipation (CIC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
World Recent Past, Current & Future Analysis for Irritable Bowel Syndrome with Constipation (IBS-C) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
World Historic Review for Irritable Bowel Syndrome with Constipation (IBS-C) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
World 16-Year Perspective for Irritable Bowel Syndrome with Constipation (IBS-C) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
World Recent Past, Current & Future Analysis for Opioid-Induced Constipation (OIC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
World Historic Review for Opioid-Induced Constipation (OIC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
World 16-Year Perspective for Opioid-Induced Constipation (OIC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
UNITED STATES
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
USA Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
USA Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
USA 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
USA Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
USA Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
USA 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
CANADA
Canada Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Canada Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Canada 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Canada Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Canada Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Canada 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
JAPAN
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
Japan Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Japan Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Japan 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Japan Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Japan Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Japan 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
CHINA
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
China Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
China Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
China 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
China Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
China Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
China 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
EUROPE
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Europe Recent Past, Current & Future Analysis for Constipation Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Europe Historic Review for Constipation Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Europe 16-Year Perspective for Constipation Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
Europe Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Europe Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Europe 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Europe Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Europe Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Europe 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
FRANCE
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
France Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
France Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
France 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
France Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
France Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
France 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
GERMANY
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
Germany Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Germany Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Germany 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Germany Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Germany Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Germany 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
ITALY
Italy Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Italy Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Italy 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Italy Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Italy Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Italy 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
UNITED KINGDOM
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
UK Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
UK Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
UK 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
UK Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
UK Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
UK 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
SPAIN
Spain Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Spain Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Spain 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Spain Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Spain Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Spain 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
RUSSIA
Russia Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Russia Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Russia 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Russia Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Russia Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Russia 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Rest of Europe Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Rest of Europe 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Rest of Europe Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Rest of Europe Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Rest of Europe 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Asia-Pacific Recent Past, Current & Future Analysis for Constipation Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Asia-Pacific Historic Review for Constipation Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Asia-Pacific 16-Year Perspective for Constipation Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
Asia-Pacific Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Asia-Pacific Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Asia-Pacific 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Asia-Pacific Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Asia-Pacific Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Asia-Pacific 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
AUSTRALIA
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
Australia Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Australia Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Australia 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Australia Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Australia Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Australia 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
INDIA
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
India Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
India Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
India 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
India Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
India Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
India 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
SOUTH KOREA
South Korea Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
South Korea Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
South Korea 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
South Korea Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
South Korea Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
South Korea 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Rest of Asia-Pacific Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Rest of Asia-Pacific 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Rest of Asia-Pacific Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Rest of Asia-Pacific 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
LATIN AMERICA
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
Latin America Recent Past, Current & Future Analysis for Constipation Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Latin America Historic Review for Constipation Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Latin America 16-Year Perspective for Constipation Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
Latin America Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Latin America Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Latin America 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Latin America Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Latin America Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Latin America 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
ARGENTINA
Argentina Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Argentina Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Argentina 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Argentina Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Argentina Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Argentina 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
BRAZIL
Brazil Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Brazil Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Brazil 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Brazil Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Brazil Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Brazil 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
MEXICO
Mexico Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Mexico Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Mexico 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Mexico Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Mexico Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Mexico 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
Rest of Latin America Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Rest of Latin America Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Rest of Latin America 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Rest of Latin America Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Rest of Latin America Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Rest of Latin America 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
MIDDLE EAST
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
Middle East Recent Past, Current & Future Analysis for Constipation Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Middle East Historic Review for Constipation Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Middle East 16-Year Perspective for Constipation Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
Middle East Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Middle East Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Middle East 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Middle East Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Middle East Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Middle East 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
IRAN
Iran Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Iran Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Iran 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Iran Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Iran Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Iran 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
ISRAEL
Israel Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Israel Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Israel 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Israel Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Israel Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Israel 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
SAUDI ARABIA
Saudi Arabia Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Saudi Arabia Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Saudi Arabia 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Saudi Arabia Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Saudi Arabia Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Saudi Arabia 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
UAE Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
UAE Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
UAE 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
UAE Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
UAE Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
UAE 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
Rest of Middle East Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Rest of Middle East Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Rest of Middle East 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Rest of Middle East Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Rest of Middle East Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Rest of Middle East 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030
AFRICA
Constipation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
Africa Recent Past, Current & Future Analysis for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Africa Historic Review for Constipation Treatment by Therapeutic Option - Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Africa 16-Year Perspective for Constipation Treatment by Therapeutic Option - Percentage Breakdown of Value Sales for Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists and 5-HT4 Receptor Agonists for the Years 2014, 2024 & 2030
Africa Recent Past, Current & Future Analysis for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Africa Historic Review for Constipation Treatment by Disease Type - Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Africa 16-Year Perspective for Constipation Treatment by Disease Type - Percentage Breakdown of Value Sales for Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC) for the Years 2014, 2024 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

%

VALIDATED RESEARCH *

* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com

[chatbot]